An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

NCT01186939 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene